Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team

• Published in: Clinical infectious diseases Vol. 63; no. suppl 2; pp. S39 - S45
• Main Authors: Donnelly, Helen, Alemayehu, Demissie, Botgros, Radu, Comic-Savic, Sabrina, Eisenstein, Barry, Lorenz, Benjamin, Merchant, Kunal, Pelfrene, Eric, Reith, Christina, Santiago, Jonas, Tiernan, Rosemary, Wunderink, Richard, Tenaerts, Pamela, Knirsch, Charles
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 15-08-2016
• Subjects: Anti-Bacterial Agents - therapeutic use; Bacteria; Clinical trials; Clinical Trials as Topic - methods; Data Collection - methods; Humans; Patient Safety; Pneumonia; Pneumonia, Bacterial - drug therapy; Pneumonia, Ventilator-Associated - drug therapy; Public-Private Sector Partnerships; Treatment Outcome; United States; Ventilators; ventilator-associated bacterial pneumonia; CTTI; clinical trials; data collection; hospital-acquired bacterial pneumonia
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciw316

Background. Resistant bacteria are one of the leading causes of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). HABP/VABP trials are complex and difficult to conduct due to the large number of medical procedures, adverse events, and concomitant medications involved. Differences in the legislative frameworks between different regions of the world may also lead to excessive data collection. The Clinical Trials Transformation Initiative (CTTI) seeks to advance antibacterial drug development (ABDD) by streamlining clinical trials to improve efficiency and feasibility while maintaining ethical rigor, patient safety, information value, and scientific validity. Methods. In 2013, CTTI engaged a multidisciplinary group of experts to discuss challenges impeding the conduct of HABP/VABP trials. Separate workstreams identified challenges associated with current data collection processes. Experts defined "data collection" as the act of capturing and reporting certain data on the case report form as opposed to recording of data as part of routine clinical care. The ABDD Project Team developed strategies for streamlining safety data collection in HABP/VABP trials using a Quality by Design approach. Results. Current safety data collection processes in HABP/VABP trials often include extraneous information. More targeted strategies for safety data collection in HABP/VABP trials will rely on optimal protocol design and prespecification of which safety data are essential to satisfy regulatory reporting requirements. Conclusions. A consensus and a cultural change in clinical trial design and conduct, which involve recognition of the need for more efficient data collection, are urgently needed to advance ABDD and to improve HABP/VABP trials in particular.